Peptide library / Digestive & weight / Pemvidutide
Pemvidutide
An investigational GLP-1 and glucagon dual agonist from Altimmune, aimed at fatty liver disease.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Reduction in liver fat in MASHSmall human studies
- Weight loss in obesitySmall human studies
How it is thought to work
Pemvidutide balances GLP-1 and glucagon activity, with the intent of reducing liver fat and body weight together.
What the evidence shows
A phase 2 trial in people with fatty liver disease showed large reductions in liver fat at 24 weeks. Histology results from the same trial were more mixed.
Safety and unknowns
Nausea, vomiting and diarrhea were the most common effects.
Regulatory status
Not approved. Phase 3 planning is under way.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Petrelintide
In clinical trialsAn investigational long-acting amylin analog from Zealand Pharma and Roche.
Plecanatide
FDA-approvedA 16 amino acid guanylate cyclase-C agonist for constipation and irritable bowel syndrome.
Oxyntomodulin
Wellness and performanceA natural gut hormone that activates both GLP-1 and glucagon receptors, and inspired later dual agonists.
General information, not medical advice. Do not buy or inject unregulated peptides.